Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
Bita FakhriNnadozie EmechebeBeenish S ManzoorDureshahwar JawaidHasan AlhasaniMelanie EdwardsHande H TuncerPublished in: JCO oncology practice (2024)
Venetoclax was associated with total monthly cost savings versus BTKis, illustrating the economic value of time-limited venetoclax-based regimens in the 2L setting.